Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
|
|
- Morris Richardson
- 5 years ago
- Views:
Transcription
1 Should we treat everybody over 60 years with a statin? Comprehensive primary prevention in practice
2 Pathogenesis of atherosclerosis A decades-long disease course Inflammation Selectins ICAM IL M-CSF CRP Endothelial stress BP Smoking VLDL LDL HDL Age decade Libby (2001) Circulation 104:365
3 Comprehensive primary prevention in practice Assessing the risks and benefits of age-determined intervention for all. The evidence base for primary prevention. Optimising primary prevention strategies.
4 Impact of age on CHD risk Ridker et al (2016) Europ Heart J. June online
5 EAS/ ESC Guidelines 2011 Concept of age linked intervention Catapano et al (2011) Atherosclerosis 217:3-46
6 Perceptions of risk
7 Response to UK NICE widening of statin use in primary prevention Statins: Millions more to get drugs in controversial plans Comments (235) 2 May 2014 By James Gallagher Health editor, BBC News website Doctors have been told to offer cholesterol-lowering statins to millions more people in a massive and controversial expansion in prescribing. Four in 10 adults in England, Wales and Northern Ireland are now eligible for statins, even though many are at low risk of a heart attack or stroke. May 15 th 2016 But cardiologist Dr Aseem Malhotra said: 'I have no doubt millions of people taking statins in the UK will not benefit but are being put at risk of unnecessary harm.' Concerns about statins were raised earlier this year by the Queen's former doctor, Sir Richard Thompson.
8 Assessing statin intolerance GAUSS -3 experience All subjects in Phase A identified as statin intolerant (80% to 3 agents) Nissen et al. JAMA. 2016;315:
9 Comprehensive primary prevention in practice Assessing the risks and benefits of age-determined intervention for all. The evidence base for primary prevention. Optimising primary prevention strategies.
10 Disease trajectories in CHD prevention Asymptomatic phase Plaque rupture Postponement of coronary event Statin Rx Statin Plus Rx Clinical event horizon Total modifiable risk Residual modifiable risk Non-modifiable risk age, sex, genetics Fatty streak Unstable lesion Stable lesion Age (years) Packard CJ, Weintraub WS, Laufs U. Vascul Pharmacol. (2015); 71:37-9
11 Placebo MI rate per 100 subjects per 5 years Assessing benefit of lipid lowering Placebo - Statin outcome trials Continuum of risk End stage Secondary prevention Primary prevention CORONA GISSI-HF (rosuvastatin) 4S (simvastatin) HPS (simvastatin) CARE (pravastatin) LIPID (pravastatin) PROSPER (pravastatin) WOSCOPS (pravastatin) AFCAPS/TexCAPS (lovastatin) JUPITER (rosuvastatin) Heart failure High-risk CHD patients (high cholesterol) Majority of CHD patients (broad range of cholesterol levels) Patients at high risk of CHD (high cholesterol) Patients at low risk of CHD (low HDL-C)
12 Relative risk reduction Lessons from completed LDL lowering trials Risk reduction is related to LDL decrease Data from trials of:- Statin vs placebo More vs less intense statin therapy. Combination therapy with ezetimibe LDLc reduction (mmol/l) Regression line reveals:- 1.0 mmol/l fall in LDLc translates into a 22% decrease in risk CTTC Lancet (2005) 367; Cannon et al NEJM (2015) 367; June
13 Modelling impact of cholesterol lowering therapy at age 60 y. Rx Atorvastatin 20mg daily Average LDL = 130 mg/dl (3.4 mmol/l) LDL decrease = 45% (1.53 mmol/l) Relative risk reduction = 33% Age 60 years 10 year CHD event rate = 18% (SCOREx3) Events prevented per 1000 = 60 NNT 10 years = 16 Based on Prospective Studies Collaboration Lancet (20107) 370:
14 Percentage with event Assessing long term (lifetime) benefits of LDL lowering in WOSCOPS CHD mortality All-cause mortality Heart failure Over entire period 27% risk reduction P<0.001 Placebo Original trial Pravastatin Years since randomisation y Average age of cohort Over entire period 13% risk reduction P<0.001 Placebo Pravastatin Years since randomisation Over 20 years HR 0.69, P= Years since randomisation Ford I et al. Circulation. (2016); 133:
15 Long term safety in statin studies WOSCOPS 20 year experience Placebo, number (%) with event Pravastatin, number (%) with event Adjusted Hazard Ratio Endpoint Total n=3293 Total n=3302 (95% Confidence Interval) P- Value All cancers 816 ( 24.8%) 809 ( 24.5%) 0.96 ( 0.87, 1.06) 0.41 Colorectal cancer 140 ( 4.25%) 127 ( 3.85%) 0.87 ( 0.68, 1.10) 0.25 Lung cancer 202 ( 6.13%) 187 ( 5.66%) 0.89 ( 0.73, 1.08) 0.24 Prostate cancer 170 ( 5.16%) 186 ( 5.63%) 1.05 ( 0.85, 1.29) 0.65 Upper GI cancer 77 ( 2.34%) 87 ( 2.63%) 1.09 ( 0.80, 1.48) 0.60 Urinary tract cancer 97 ( 2.95%) 99 ( 3.00%) 0.99 ( 0.75, 1.31) 0.93 Other cancer 160 ( 4.86%) 157 ( 4.75%) 0.95 ( 0.76, 1.18) 0.62 All non-cvd deaths 757 ( 23.0%) 731 ( 22.1%) 0.92 ( 0.83, 1.02) 0.12
16 WOSCOPS - in trial and post trial event rates Placebo, number (%) with event Total n = 3293 In trial event rates ( ) In trial Pravastatin, number (%) with event Adjusted Hazard Ratio (95% CI) Endpoint Total n = 3302 P-value* Fatal or nonfatal MI 190 ( 5.77%) 115 ( 3.48%) 0.59 ( 0.47, 0.74), < Placebo, number (%) with event Post trial Pravastatin, number (%) with event Adjusted Hazard Ratio (95% CI) Total n = 3023 Total n = 3118 P-value* 427 ( 14.13%) 372 ( 11.93%) 0.82 ( 0.71, 0.94), CHD related death or nonfatal MI 198 ( 6.01%) 119 ( 3.60%) 0.58 ( 0.47, 0.73), < ( 15.88%) 418 ( 13.41%) 0.82 ( 0.72, 0.93), CHD related death or hospitalisation 273 ( 8.29%) 177 ( 5.36%) 0.58 ( 0.47, 0.72), < ( 27.92%) 739 ( 24.12%) 0.79 ( 0.70, 0.89), CV related death or hospitalisation 415 ( 12.60%) 329 ( 9.96%) 0.62 ( 0.52, 0.73), < ( 46.05%) 1215 ( 41.51%) 0.81 ( 0.73, 0.90), < Fatal or nonfatal stroke 40 ( 1.21%) 29 ( 0.88%) 0.56 ( 0.31, 1.03), ( 10.61%) 329 ( 10.36%) 1.00 ( 0.82, 1.22), Ford I et al. Circulation. (2016); 133:
17 Cumulative CHD burden 20 years in 72,000 WOSCOPS screened men Group (n) Mean cholesterol [LDL] (mmol/l) Observed CHD hospitalisation events per 100 subjects over 20 years Observed CHD hospital days per 100 subjects over 20 years No CHD history primary prevention Adjusted hazard ratio a (95% CI) P4 (10767) 7.05 [5.0] ( ) NNT = 3-4 P3 (22288) 5.98 [4.0] ( ) P2 (18952) 5.06 [3.1] ( ) P1 (7414) 4.00 [2.1] (referent) With CHD history secondary prevention S4 (2210) 7.10 [5.1] ( ) NNT = 1-2 S3 (3105) 6.02 [4.0] ( ) S2 (2037) 5.08 [3.1] ( ) S1 (741) 3.98 [2.0] (referent)
18 Comprehensive primary prevention in practice Assessing the risks and benefits of age-determined intervention for all. The evidence base for primary prevention. Optimising primary prevention strategies.
19 Pathogenesis of atherosclerosis Asymptomatic early lesions Clinically significant pathology Raised fatty streaks Complex/ ulcerated plaques
20 Percentage with event Intervention versus prevention Non-fatal MI/ CHD death 24 Gain in event free years years placebo pravastatin Years since randomisation
21 Costs decrease Costs increase Benefits of primary prevention Clinical benefit is evident in low risk populations Statin therapy is cost-saving over long term in primary prevention WOSCOPS Cumulative costs per 1000 statin treated subjects (CVD Hospitalisation; drug, monitoring) 200k 0 200k 400k 600k 800k 1000k 1200k CTTC Lancet May 2012 (on-line) McConnachie, Ford, Packard et al (WOSCOPS,unpublished)
22 Troponin as an index of cardiomyocyte damage or stress Troponin T, I, C complex with actino-myosin in cardiac muscle
23 Troponin I and CVD risk in a primary prevention population - WOSCOPS Troponin I measured at baseline (pre treatment) Q4 vs Q1 HR 2.27 Ford et al JACC (2016) 68:
24 Dynamic measures of atherosclerosis progression Troponin I measured at baseline and Year 1 on treatment. HR 5 to 6 for primary endpoint for Q4 vs Q1. Why is change in trop I a stronger predictor of risk? TnI increased over Year 1 TnI decreased over Year 1 Ford et al JACC (2016) 68:
25 LDL lowering in primary prevention Targeting based on gene score Khera et al N.Eng. J Med. (2016) Nov 13 Mega et al Lancet (2015) 385:
26 An age-based plan for comprehensive primary CVD prevention Selective screening. Family history of CHD. Genetic testing Risk factor + Biomarker (TnI, BNP) assessment. Bi-annual check. Offer statin to all. Compliance. Side effects.
27 Summary Age is the single most important determinant of CHD risk. An argument can be made for universal statin therapy initiation at a age linked to high risk (7.5% to 10%/ 10 years). Benefits clear from trial evidence base long term safety and efficacy. Risk appreciation and adherence are challenges. Strategy is clinically effective but socially acceptance is yet to be proven.
28 End 45 mins
29 LDL and atherosclerosis A coalescence of evidence Genomics Genetics Epidemiology Pathology Intervention trials
30 Pharmacological CHD prevention in populations Prescribe statins to those at risk at 40, study says (July 2009)
31 EAS/ ESC Guidelines 2011 Impact of age on CHD risk Catapano et al (2011) Atherosclerosis 217:3-46
32 Role of LDL in atherogenesis Cellular remodelling Release of bio-active lipids Extracellular pathology Lipoprotein retention Deposits early microand later macrocholesterol crystals. Innate immunity Initiates localised inflammation. Macrophage recruitment. Intracellular cholesterol accumulation. Necrosis Auto-immunity (apob) Adaptive immunity See Libby, Ridker, Hansson. Nature (2011); 473:
33 Event rate (%) Association of LDL cholesterol with CHD risk in statin trials 30 4S - Placebo Rx - Statin therapy PRA pravastatin ATV - atorvastatin 4S - Rx Secondary Prevention (0.5) LIPID - Rx CARE - Placebo CARE - Rx HPS - Rx TNT ATV10 HPS - Placebo TNT ATV80 PROVE-IT - PRA WOSCOPS Placebo PROVE-IT ATV AFCAPS - Placebo IMPROVE-IT sim IMPROVE-IT e/s 6 AFCAPS - Rx WOSCOPS - Rx JUPITER -RSV JUPITER - Placebo ASCOT - Placebo ASCOT - Rx 40 (1.0) 60 (1.6) 80 (2.1) 100 (2.6) 120 (3.1) LDL-C achieved mg/dl (mmol/l) 140 (3.6) LIPID - Placebo 160 (4.1) Primary Prevention 180 (4.7) 200 (5.2) Adapted from Rosensen RS. Exp Opin Emerg Drugs 2004;9(2): LaRosa JC et al. N Engl J Med 2005;352:e-version
34 Relative risk reduction Exploring LDL lowering strategies using inherited variation LDL lowering due to variation in:- Cholesterol absorption (ezetimibe) Cholesterol production (statin) LDL receptor number (PCSK9 inhibitor) LDLc reduction (mmol/l) CHD risk reduction per unit LDL decrease is independent of intervention target. Ference et al JACC (2015) March on-line
35 Inherited vs pharmacologically based LDL lowering Earlier is better Ference et al JACC (2015) March (0n-line)
36 Event (%) WOSCOPS: Early Event Reductions With Pravastatin Myocardial Infarction Placebo (n = 3293) Pravastatin (n = 3302) Years in Study 31% risk reduction P < Cardiovascular Mortality Placebo (n = 3293) Pravastatin (n = 3302) Years in Study 32% risk reduction P = Total Mortality Placebo (n = 3293) Pravastatin (n = 3302) Years in Study 22% risk reduction P = PTCA/CABG Placebo (n = 3293) Pravastatin (n = 3302) Years in Study 37% risk reduction P = Shepherd et al. N Engl J Med. 1995;333:
37 % Long term safety of statins WOSCOPS: 15 year follow up CHD-related death or nonfatal MI Risk reduction in statin group 40% during trial (P<0.001) 18% post-trial (P=0.02) 27% overall follow-up (P<0.001) Years post-trial Placebo Pravastatin K-M curves according to the originally assigned study group Ford I et al. N Engl J Med 2007;357:
38 Options in LDL lowering High dose statin vs. combination therapy 21 st March 2014 AE profile High vs moderate dose statin Event Odds ratio(ci) Any AE 1.44( ) LFT abnormalities 4.48( ) CK> ( ) Rhabdomyolysis 1.66( ) Silva et al (2007) Clin. Therap. 29:
39 Percentage with event Additional/ long term benefits of LDL lowering in heart failure Effect of statin therapy on non-fatal/ fatal heart failure in 14 LDL lowering trials WOSCOPS Heart failure hospitalisations 5 4 Over 20 years HR 0.69, P= Overall (I 2 =0.0%, P=0.757) 0.90 (0.84, 0.97) Years since randomisation Relative risk Preiss et al EHJ (2015) March on-line
40 Potential mechanism of a legacy effect in LDL lowering trials (HPS) (WOSCOPS) Packard, Ford Curr Opin Lipidol (2015) 26;572-9
41 Troponin I is decreased by statins LDL lowering with pravastatin moved subjects to lower quintiles of change in trop I.? LDL lowering induced net repair.? Change in trop I as biomarker of atherosclerosis progression. Ford et al JACC (2016) 68:
42 Legacy benefit in statin trials - ASCOT Lipid changes Primary endpoint Sever et al Europ Heart J(2008) 29;
43 Damage and repair in the natural history of atherosclerosis Troponin I in asymptomatic subjects is a measure of micro-damage possibly ruprure and repair of atheromatous lesions Change in trop I is a stronger predictor of because it identifies repairers and nonrepairers. Rupture Trop I Small lesion Microthrombus Repair Healed plaque Trop I
44 Legacy benefit in statin trials - HPS HPS Collaborative Group Lancet (2011) 378;
45 Emerging Risk Factors Collaboration Plasma lipids and incident CHD 302,430 subjects; 2.79 million pt-yrs; 8857 MIs; 3928 strokes; 68 studies Danesh et al (2009) JAMA 302:
46 CHD (fatal +non-fatal) event rate per 5 years - Secondary prevention trials CHD (fatal +non-fatal) event rate per 5 years - Primary prevention trials Achieved LDL in primary and secondary prevention trials 9,0 25,0 4S-p WOSCOPS-p 8,0 20,0 15,0 10,0 5,0 ASCOT-p WOSCOPS-a LIPID-p PROSPER-a IDEAL-s PROSPER-p CARE-p CARE-a HPS-p IDEAL-a AFCAPS-a LIPID-a ASCOT-a HPS-a TNT-10 JUPITER-p TNT-80 JUPITER-a 4S-a AFCAPS-p 7,0 6,0 5,0 4,0 3,0 2,0 1,0 0,0 0, Achieved LDL cholesterol (mg/dl)
47 Clinical Benefit of Lowering LDL-C Earlier Baseline LDL-C mg/dl (mmol/l) LDL-C after 50% reduction RR for CHD* Relative Reduction in Lifetime Risk 190 (4.9) 95 (2.5) % 160 (4.1) 80 (2.1) % 140 (3.6) 70 (1.8) % 120 (3.1) 60 (1.6) % 100 (2.6) 50 (1.3) % 80 (2.1) 40 (1.0) % * Based on 54% RRR per mmol/l lifetime exposure to lower LDL-C. Calculated as RR = 0.46 (Δ in mmol/l) ACC/AHA Guidelines recommend treating threshold of 190 mg/dl However, similar very large lifetime risk reduction for persons with LDL-C well below 190 mg/dl Ference, BA et al. J Am Coll Cardiol 2012;60: Ference, BA et al. J Am Coll Cardiol 2015;
48 Long term benefit in statin trials PROSPER long-term followup (Scottish cohort) Coronary death or hospitalisation for MI Endpoint Placebo (n) In trial Post trial Pravastatin (n) Placebo (n) Pravastatin (n) Original trial Placebo CHD+stroke death or admission Risk ratio 0.80 ( ) 0.96 ( ) Pravastatin y Average age of cohort CHD death or CHD admission Risk ratio 0.74 ( ) Lloyd et al, PLoS ONE (2013) 8; e ( ) Does the strength of the legacy benefit depend on the age treatment is started?
49 Disease trajectories in CHD prevention Asymptomatic phase Plaque rupture Postponement of coronary event Gain in Event Free Years Statin Rx Statin Plus Rx Clinical event horizon Primordial prevention of atherogenesis Total modifiable risk Residual modifiable risk Non-modifiable risk age, sex, genetics Fatty streak Unstable lesion Stable lesion Age (years)
CLINICAL OUTCOME Vs SURROGATE MARKER
CLINICAL OUTCOME Vs SURROGATE MARKER Statin Real Experience Dr. Mostafa Sherif Senior Medical Manager Pfizer Egypt & Sudan Objective Difference between Clinical outcome and surrogate marker Proper Clinical
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationLDL cholesterol and cardiovascular outcomes?
LDL cholesterol and cardiovascular outcomes? Prof Kausik Ray, BSc (hons), MBChB, FRCP, MD, MPhil (Cantab), FACC, FESC Professor of Cardiovascular Disease Prevention St Georges University of London Honorary
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationLifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study
Lifetime clinical and economic benefits of statin-based LDL lowering in the 20-year Followup of the West of Scotland Coronary Prevention Study Harvey White Green Lane Cardiovascular Service and Cardiovascular
More informationJUPITER NEJM Poll. Panel Discussion: Literature that Should Have an Impact on our Practice: The JUPITER Study
Panel Discussion: Literature that Should Have an Impact on our Practice: The Study Kaiser COAST 11 th Annual Conference Maui, August 2009 Robert Blumberg, MD, FACC Ralph Brindis, MD, MPH, FACC Primary
More informationHow to Reduce Residual Risk in Primary Prevention
How to Reduce Residual Risk in Primary Prevention Helene Glassberg, MD Assistant Professor of Medicine Section of Cardiology Hospital of the University of Pennsylvania Philadelphia, PA USA Patients with
More informationStatins for Cardiovascular Disease Prevention in Women: Review of the Evidence
Statins for Cardiovascular Disease Prevention in Women: Review of the Evidence Karen E. Aspry, M.D., M.S., ABCL, FACC Assistant Professor of Medicine (Clinical) Alpert Medical School of Brown University
More informationAn example of a systematic review and meta-analysis
An example of a systematic review and meta-analysis Sattar N et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010; 375: 735-742. Search strategy
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationWeigh the benefit of statin treatment: LDL & Beyond
Weigh the benefit of statin treatment: LDL & Beyond Duk-Woo Park, MD, PhD Heart Institute, University of Ulsan College of Medicine, Asan Medical, Seoul, Korea FOURIER Further cardiovascular OUtcomes Research
More informationIs it an era for statin for life?
Is it an era for statin for life? Mohamed Abdel Ghany Professor of Cardiology Cairo University Cardiovascular Disease (CVD) is the leading global cause of death 1 Dyslipidemia as a main Risk Factor for
More informationCalculating RR, ARR, NNT
Calculating RR, ARR, NNT In a trial RR = Event rate (eg # of people with one stroke/ total people) in treatment group/event rate in the control group. ARR = Event rate in control group minus the event
More informationWhat have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline?
What have We Learned in Dyslipidemia Management Since the Publication of the 2013 ACC/AHA Guideline? Salim S. Virani, MD, PhD, FACC, FAHA Associate Professor, Section of Cardiovascular Research Baylor
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationCase Presentation. Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer
Case Presentation Rafael Bitzur The Bert W Strassburger Lipid Center Sheba Medical Center Tel Hashomer Case Presentation 50 YO man NSTEMI treated with PCI 1 month ago Medical History: Obesity: BMI 32,
More informationNicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist
1 Nicole Ciffone, MS, ANP-C, AACC Clinical Lipid Specialist New Cardiovascular Horizons Multidisciplinary Strategies for Optimal Cardiovascular Care February 7, 2015 2 Objectives After participating in
More informationThe Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C
The Atherogenic Dyslipidemia of Diabetes Mellitus- Not just a question of LDL-C Eun-Jung Rhee Department of Endocrinology and Metabolism Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
More informationLAMIS (Livalo in AMI Study)
JCR 2018. 12. 8 LAMIS (Livalo in AMI Study) Young Joon Hong Division of Cardiology, Chonnam National University Hospital Gwangju, Korea Trend of hypercholesterolemia in Korea < Prevalence of hypercholesterolemia
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationLessons from Recent Atherosclerosis Trials
Lessons from Recent Atherosclerosis Trials Han, Ki Hoon MD PhD Asan Medical Center Seoul, Korea Change of concept Primary vs. secondary prevention Low risk vs. High risk High Risk CHD and equivalents CHD
More informationFasting or non fasting?
Vascular harmony Robert Chilton Professor of Medicine University of Texas Health Science Center Director of Cardiac Catheterization labs Director of clinical proteomics Which is best to measure Lower continues
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationNew ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough?
New ACC/AHA Guidelines on Lipids: Are PCSK9 Inhibitors Poised for a Breakthrough? Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of North Carolina at Chapel Hill Immediate
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationInflammation and and Heart Heart Disease in Women Inflammation and Heart Disease
Inflammation and Heart Disease in Women Inflammation and Heart Disease What is the link between een inflammation and atherosclerotic disease? What is the role of biomarkers in predicting cardiovascular
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More information2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice
2016 ESC/EAS Guideline in Dyslipidemias: Impact on Treatment& Clinical Practice Nattawut Wongpraparut, MD, FACP, FACC, FSCAI Associate Professor of Medicine, Division of Cardiology, Department of Medicine
More informationReducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)
New York City Cardiovascular Symposium December 10, 2017 Reducing Inflammation to Reduce Cardiovascular Risk: The Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS) Paul M Ridker, MD, MPH
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationLDL and the Benefits of Statin Therapy
LDL and the Benefits of Statin Therapy Allan Sniderman McGill University ACC/AHA did not recommend a target-based approach. Right? P 2899 The Expert Panel was unable to find any RCTs that evaluated titration
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationSeung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI, FESC, FAPSIC. Cardiovascular Center, Korea University Guro Hospital
Novel Statin Strategy to Prevent Atherosclerotic Cardiovascular Disease in Diabetic Patients-Curtailing Heart Attack : Korean Data and JUPITER again in spotlight Seung-Woon Rha, MD, PhD, FACC, FAHA, FSCAI,
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationCholesterol Treatment Update
Cholesterol Treatment Update Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public Health Disclosure:
More information10/15/2012. Lessons Learned from Tim Russert: Investigating Residual Risk. Tim Russert: Residual CV Risk?
Lessons Learned from Tim Russert: Investigating Residual Risk Peter H. Jones, MD, FACP Associate Professor Methodist DeBakey Heart and Vascular Center Baylor College of Medicine Houston, Texas Tim Russert:
More informationDyslipidemia: Lots of Good Evidence, Less Good Interpretation.
Dyslipidemia: Lots of Good Evidence, Less Good Interpretation. G Michael Allan Evidence & CPD Program, ACFP Associate Professor, Dept of Family, U of A. CFPC CoI Templates: Slide 1 Faculty/Presenter Disclosure
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationA Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life
A Mendelian Randomized Controlled Trial of Long Term Reduction in Low-Density Lipoprotein Cholesterol Beginning Early in Life Brian A. Ference, M.D., M.Phil., M.Sc. ACC.12 Chicago 26 March 2012 Disclosures
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationCanakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS) Stable CAD (post MI) On Statin, ACE/ARB, BB, ASA Persistent Elevation of hscrp (> 2 mg/l) N = 10,061 39 Countries April 2011 - June 2017
More informationBest Lipid Treatments
Best Lipid Treatments Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Overview of Talk Review of pathogenesis
More informationHyperlipidemia: Lowering the Bar on the Lipid Limbo. Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH
Mark slides Hyperlipidemia: Lowering the Bar on the Lipid Limbo Community Faculty Development Symposium March 13, 2004 Hugh Huizenga MD, MPH Hyperlipidemia is a common problem Nearly 50% of men in the
More informationThe Clinical Debates
The Clinical Debates Speakers: Round 2: Statins for Primary Prevention of Cardiovascular Disease Matthew Cantrell, PharmD, BCPS, is a 2000 graduate of Mt. Mercy College and 2005 graduate from the University
More informationPCSK9 Inhibitors and Modulators
PCSK9 Inhibitors and Modulators Pam R. Taub MD, FACC Director of Step Family Cardiac Rehabilitation and Wellness Center Associate Professor of Medicine UC San Diego Health System Disclosures Speaker s
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationPlacebo-Controlled Statin Trials Prevention Of CVD in Women"
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationWhat do the guidelines say about combination therapy?
What do the guidelines say about combination therapy? Christie M. Ballantyne, MD Center for Cardiovascular Disease Prevention Methodist DeBakey Heart & Vascular Center Baylor College of Medicine Houston,
More informationDyslipidemia 울산의대서울아산병원심장병원심장내과이철환
Dyslipidemia 울산의대서울아산병원심장병원심장내과이철환 Presentation General LDL cholesterol HDL cholesterol Future Summary A top healthcare priority 사망 / 인구 10 만 Causes of Death Worldwide, 2008 140 120 2008 년 한국인 5 대사망원인
More informationConsiderations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction
Considerations and Controversies in the Management of Dyslipidemia for ASCVD Risk Reduction Pamela B. Morris, MD, FACC, FAHA, FASCP, FNLA Chair, ACC Prevention of Cardiovascular Disease Council The Medical
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationPlacebo-Controlled Statin Trials MANAGEMENT OF HIGH BLOOD CHOLESTEROL MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES
MANAGEMENT OF HIGH BLOOD CHOLESTEROL: IMPLICATIONS OF THE NEW GUIDELINES Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationIn-Ho Chae. Seoul National University College of Medicine
The Earlier, The Better: Quantum Progress in ACS In-Ho Chae Seoul National University College of Medicine Quantum Leap in Statin Landmark Trials in ACS patients Randomized Controlled Studies of Lipid-Lowering
More informationDyslipedemia New Guidelines
Dyslipedemia New Guidelines New ACC/AHA Prevention Guidelines on Blood Cholesterol November 12, 2013 Mohammed M Abd El Ghany Professor of Cardiology Cairo Universlty 1 1 0 Cholesterol Management Pharmacotherapy
More informationDecline in CV-Mortality
Lipids id 2013 What s Changed? Christopher Granger, MD Disclosure Research contracts: AstraZeneca, GSK, Merck, Sanofi- Aventis, BMS, Pfizer, The Medicines Company, Medtronic Foundation, and Boehringer
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationUpdate on Cholesterol Management: The 2013 ACC/AHA Guidelines
Update on Cholesterol Management: The 2013 ACC/AHA Guidelines Ola Akinboboye MD MPH MBA Medical Director, Queens Heart institute Rosedale. Associate Professor of Clinical Medicine, Weill Medical College
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationGet a Statin or Not? Learning objectives. Presentation overview 4/3/2018. Treatment Strategies in Dyslipidemia Management
Get a Statin or Not? Treatment Strategies in Dyslipidemia Management Michelle Chu, PharmD, BCACP, CDE Assistant Professor of Clinical Pharmacy, USC School of Pharmacy Sahar Dagher, PharmD Virtual Care
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationDisclosures No relationships (not even to an employer) No off-label uses. Cholesterol Lowering Guidelines: What now?
Disclosures No relationships (not even to an employer) No off-label uses Cholesterol Lowering Guidelines: What now?, FACP 1 2 65-year-old white woman Total cholesterol 175mg/dL HDL 54 mg/dl LDL 96 mg/dl
More informationInflammation as A Target for Therapy. Focus on Residual Inflammatory Risk
ESC Rome Monday August 29, 2016 Inflammation as A Target for Therapy Focus on Residual Inflammatory Risk Paul M Ridker, MD Eugene Braunwald Professor of Medicine Harvard Medical School Director, Center
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationIschemic Heart and Cerebrovascular Disease. Harold E. Lebovitz, MD, FACE Kathmandu November 2010
Ischemic Heart and Cerebrovascular Disease Harold E. Lebovitz, MD, FACE Kathmandu November 2010 Relationships Between Diabetes and Ischemic Heart Disease Risk of Cardiovascular Disease in Different Categories
More informationWhat Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment?
What Role do the New PCSK9 Inhibitors Have in Lipid Lowering Treatment? Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director, Prevention Intervention Center University
More informationNovel PCSK9 Outcomes. in Perspective: Lessons from FOURIER & ODYSSEY LDL-C. ASCVD Risk. Suboptimal Statin Therapy
LDL-C Novel PCSK9 Outcomes Suboptimal Statin Therapy ASCVD Risk in Perspective: Lessons from FOURIER & ODYSSEY Jennifer G. Robinson, MD, MPH Professor, Departments of Epidemiology & Medicine Director,
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationEvaluation of C-reactive protein prior to and on-treatment as a predictor of benefit
Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin. A cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm Peter S Sever,
More informationPREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationContemporary management of Dyslipidemia
Contemporary management of Dyslipidemia Todd Anderson Feb 2018 Disclosure Statement Within the past two years: I have not had an affiliation (financial or otherwise) with a commercial organization that
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationNew Cholesterol Guidelines What the LDL are we supposed to do now?!
New Cholesterol Guidelines What the LDL are we supposed to do now?! Michael D. Shapiro Assistant Professor of Medicine and Radiology Knight Cardiovascular Institute Oregon Health & Science University 2013
More informationUpdate on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP
Update on Lipid Guidelines and Intense Treatment of LDL-C with PCSK9 Inhibitors Carl J. Lavie, MD,FACC,FACP,FCCP Professor of Medicine Medical-Director, Preventive Cardiology John Ochsner Heart and Vascular
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationManaging Dyslipidemia in Disclosures. Learning Objectives 03/05/2018. Speaker Disclosures
Managing Dyslipidemia in 2018 Glen J. Pearson, BSc, BScPhm, PharmD, FCSHP, FCCS Professor of Medicine (Cardiology) Co-Director, Cardiac Transplant Clinic; Associate Chair, Health Research Ethics Boards;
More informationPlacebo-Controlled Statin Trials
PREVENTION OF CHD WITH LIPID MANAGEMENT AND ASPIRIN: MATCHING TREATMENT TO RISK Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of
More information